A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

COVID-19 Drug Treatment Clinical Trial

Official title:

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics Among COVID-19 Patients Receiving Treatment With Nirmatrelvir/Ritonavir (PAXLOVIDTM) in Morocco.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05997485
• Other study ID #: C4671060
• Status: Withdrawn
• Start date: March 30, 2024
• Est. completion date: June 30, 2024

Study information

• Verified date: March 2024
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to collect information on the:

• general information of a group of people such as their age, sex, and other facts.

• clinical information of the patients such as any other illness before having COVID 19.

In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.

This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.

This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.

The study will include patient information of those who:

• are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023.

• are 18 years of age or older.

• are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed COVID-19 infection during the study period from 01 June 2022 to 30 June 2023

• Nirmatrelvir, ritonavir written prescription

Exclusion Criteria:

• There are no exclusion criteria for this study.

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Drug Treatment

Intervention

Drug:
• Nirmatrelvir/Ritonavir
Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demographical Characteristics of Participants		Approximately 01 June 2022 through 30 June 2023
Primary	Clinical Characteristics of Participants		Approximately 01 June 2022 through 30 June 2023
Primary	Number of Participants with Pre-existing Comorbidities		Approximately 01 June 2022 through 30 June 2023